Earnings dates and session timing shown here are aggregated from third-party sources, are frequently estimated, and are subject to change or confirmation by the reporting company. Nothing on this site is financial advice.
Candel Therapeutics Inc. is a pioneering biotechnology company focused on revolutionizing cancer treatment through its proprietary oncolytic virus platform, which uniquely targets and destroys cancer cells while preserving healthy tissue. The company has developed a promising pipeline that addresses several challenging malignancies, enhancing the body’s immune response against tumors and striving for significant advancements in therapeutic efficacy. With a solid intellectual property foundation and strategic collaborations with leading research institutions, Candel is well-positioned to be at the forefront of groundbreaking innovations in oncology, with the ultimate goal of improving patient outcomes and reshaping cancer care standards.
Quotes and fundamental data are delayed and provided for informational purposes only — nothing on this page is financial advice. Figures are as reported by the company and its data providers and may be revised. Estimates reflect analyst consensus at the time of each report.
$12.78
| Quarter | EPS | Revenue | Price move | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Est | Adj | Result | GAAP | Est | Actual | Surprise | 1D Pre | On-Day | 1D Post | |
Q ended Jun 30, 2026 Reported Aug 13, 2026 | $-0.22 | $-0.35 | Miss -59.1% | $-0.52 | $0 | $0 | — | 1D Pre+0.3% | On-Day+10.5% | 1D Post-0.7% |
Q ended Mar 31, 2026 Reported May 14, 2026 | $-0.33 | $-0.14 | Beat +57.6% | $-0.14 | $0 | $0 | — | 1D Pre+2.5% | On-Day-0.3% | 1D Post-1.6% |
Q ended Dec 31, 2025 Reported Mar 12, 2026 | $-0.24 | $-0.29 | Miss -20.8% | |||||||
Dashed outlines show the analyst consensus estimate for periods where one was published. Hover or tap a bar for exact figures. Values as reported; not adjusted for splits after the report date.
| — |
| $0 |
| $0 |
| — |
| 1D Pre-0.2% |
| On-Day-2.4% |
| 1D Post-6.2% |
Q ended Sep 30, 2025 Reported Nov 13, 2025 | $-0.18 | $-0.21 | Miss -16.7% | — | $0 | $0 | — | 1D Pre-2.0% | On-Day-6.3% | 1D Post+0.7% |